BIIB, Fumapharm Phase II psoriasis results

Biogen Idec (BIIB) and Fumapharm (Lucerne, Switzerland) said that in a double-blind, dose-ranging Phase II trial in 144 patients with severe psoriasis, 42% of patients receiving BG-12 achieved a PASI ...